Orkla ASA (ORK) Earnings Call Transcript & Summary
October 29, 2024
Earnings Call Speaker Segments
Annie Bersagel
executiveGood morning, and welcome to Orkla's presentation of third quarter results. My name is Annie Bersagel, and I'm the new Head of Investor Relations. To begin, our President and CEO, Nils Selte, will begin with a summary of the quarter. After that, our CFO, Arve Regland, will go into a deeper dive with the financials. Before we move on to Q&A, Nils will summarize some of the main messages from the quarter. Just a bit of housekeeping. So during the presentation, you're welcome to submit questions in the webcast, and we will address all your questions in the Q&A session at the end of the presentation. So I'll now leave the floor to you, Nils.
Nils Selte
executiveThank you, Annie, and good morning to all of you. On the whole, during Q3 we kept making gains in profitability as well as cash flow. Adjusted earnings per share rose 10%, and underlying EBITDA adjusted growth came in at 17% across the consolidated portfolio companies, headquarter included. That happened even though advertising and promotional spending went up significantly in the quarter. Organic growth reached 3.9% for the quarter, and 8 of 10 consolidated portfolio companies contributed positively. At the macro level, inflation rates are continuing to normalize across many of our markets. Competition from private labor is still intense, and weak consumer sentiment weighed negatively on some markets. Even so, we see that the challenges — as I mentioned, weak consumer purchasing power — have eased somewhat relative to the same quarter last year. As we noted in Q2, raw material price developments remain polarized, yet our Q3 figures show slight positive effects. Based on what we see today as we head into 2025, we expect raw material prices overall to stabilize, excluding cocoa. Finally, on cash flow: under the new operating model, we listed cash conversion as a key metric for the companies, and positive effects are showing up. Arve will come back to this later in the presentation.
Nils Selte
executiveLike I mentioned, adjusted underlying EBIT rose 17% across the entire company. Now I'll offer a handful of remarks about our biggest portfolio businesses. Jotun kept delivering results well beyond the financial targets the company has communicated. Sales were up 8% year-to-date through August, even against strong comparables. Jotun's return on capital employed came in at 34% on a rolling 12-month basis. At Orkla Foods Europe, volume growth was marginally positive this quarter, with differences between markets. Operating margins at Foods Europe kept getting better, helped along by cost reductions that are ongoing. Also, in September, Aku Vikström came aboard as the new CEO of that company. I'm delighted to have Aku with us. At Orkla Confectionery & Snacks, the operational difficulties at the biscuit factory have now been mostly worked out. Overall, we're seeing market share move in a positive direction. On volume, though, there's pressure in the chocolate category after market prices for cocoa rose extraordinarily. For Orkla Food Ingredients, both operating margin growth and volume/mix growth were positive in the Bakery and Sweet segments alike. Performance was particularly strong in the Bakery segment, in terms of both volume and margin development. Now turning to the targets we set at our Capital Markets Day.
Nils Selte
executiveThe 3 goals shown on this slide reflect the combined impact of the portfolio companies hitting their targets across the strategy period. While it's still early days, we're on track on each of these metrics. I'll now pass it over to Arve for more detail on the financials.
Arve Regland
executiveThanks, Nils, and good morning to all of you. So the third quarter came in strong for Orkla, with organic — that is, operating — growth up 4.3%, reaching NOK 17.5 billion, and EBIT adjusted rising 13%. EBIT for the consolidated portfolio companies, HQ included, was up 17%, powered by solid underlying growth and better margins across most of our portfolio companies. The drop in EBIT adjusted for Financial Investments was chiefly tied to last year's handover of apartments at Orkla Real Estate. Moving to other income and expenses, we show a negative figure of NOK 741 million for this quarter. Of that, NOK 650 million stems from 3 particular write-downs. First, we took a NOK 300 million impairment at Orkla Confectionery & Snacks, Latvia. That is not the biscuit factory — it is the business unit we acquired back in 2015, which has not demonstrated the profitability needed to justify its book value of intangibles on the balance sheet. The same logic underlies a NOK 50 million write-down of NIC Germany, which sits within the Sweet segment at Orkla Food Ingredients. And last year, we recorded a NOK 300 million write-down of a common ERP template developed under Orkla's former strategy of building one shared ERP system for all group companies — something with less relevance now that our portfolio companies operate more independently.
Arve Regland
executiveSo with that, the carrying value on the balance sheet drops from NOK 360 million to NOK 60 million. And keep in mind these write-downs don't affect cash at all. Jotun contributed NOK 548 million of profit in the quarter, which is up 8% from a year earlier. The rise in noncontrolling interest profit relates to the loans ownership in Orkla Food Ingredients. Earnings per share came in at NOK 1.18 as reported, and when you adjust for other income and expenses it's NOK 1.77 per share, which is 10% higher than last year. Broadly, we keep seeing EBIT margins edge up, hitting 10% on a rolling 12-month basis at the close of the third quarter, 30 basis points better than the prior quarter. Every one of the biggest portfolio companies posted positive EBIT adjusted margin growth, helped by favourable volume/mix development, even with higher advertising spend across the portfolio companies in line with strategy, as Nils also pointed out. Organic growth for the quarter was 3.9%, and within that 2.6% came from volume/mix, helped positively by 1 extra sales day versus last year. And as the table on the right shows, that positive volume/mix growth was broad-based across the portfolio companies.
Arve Regland
executiveOn an aggregated basis, we keep observing market conditions that are stabilizing after a stretch of strong inflationary pressure. Year-to-date, total cash flow before capital allocation came to NOK 4.9 billion, which is NOK 2.1 billion higher than last year. This cash flow format differs somewhat from the prior quarter — we're concentrating on cash flow prior to capital allocation toward M&A, CapEx, or distributions to owners. The gain in cash flow stems primarily from EBIT growth across the consolidated portfolio companies, reduced net replacement investments, a larger dividend received from Jotun, and lower taxes tied to profit in Hydro Power, though these were partly offset by weaker profit from Financial Investments. Cash flow from Financial Investments fell to roughly NOK 500 million, owing to working capital buildup in Orkla Real Estate, the handover of our apartments in Orkla Real Estate during last year, and lower profits in Hydro Power. Cash conversion across the portfolio companies stays robust, at an aggregate 112% on a rolling 12-month basis. We also keep a strong balance sheet, helped by the higher cash flow we discussed on the prior slide. That covers net cash flow from M&A as well as the larger dividend paid out to shareholders in the second quarter. Net interest-bearing debt stood at NOK 18.3 billion (sic) NOK 18.8 billion at quarter-end, equal to a net interest-bearing debt to EBITDA of 1.8x.
Arve Regland
executiveAnd once you strip out external debt and EBITDA at Orkla Food Ingredients, that ratio came to 1.4x. Now I'll take you through how the portfolio companies performed financially. To begin with Jotun, which keeps posting solid results — revenue is up 8% year-to-date, with gains in every segment and region. The Protective Coatings area was especially strong, posting double-digit sales growth. Marine also grew nicely, while Decorative Paints and powder showed a more modest trend. EBITDA rose 2.3% year-to-date, lifted by positive volume growth amid high demand across most geographies. Raw material prices have been fairly steady, though the company does face some inflationary pressure on operating costs ahead. Even so, the outlook for the rest of the year remains positive. At Orkla Foods Europe, organic growth in the quarter was 2.7%, split evenly between price and volume/mix. That volume/mix gain comes mainly from Norway, partly because of a weak July last year and partly thanks to positive out-of-home development this year. Market share keeps climbing in Denmark, and we saw a comeback in retail in the Czech Republic after price reductions.
Arve Regland
executiveWe're still seeing tough conditions in Sweden and Finland, and consumer confidence there is still subdued. Even with a big lift in A&P spending versus a year ago, underlying EBITDA rose only 17%, and the EBIT margin gained 1.6 percentage points. That improvement gets a positive boost from a sharper emphasis on category and product profitability, backed by cost savings from reorganization projects in Norway, Sweden and the Czech Republic. Keep in mind that last year's third-quarter EBIT took a negative hit from one-off costs of roughly NOK 25 million tied to a recall of catchup in several markets. Orkla Confectionery & Snacks posted organic growth of 4.4% for the quarter, carried by price, since volumes were held back by softer demand in the confectionery segments, linked to higher chocolate prices and to production issues at the BUBs factory. Those production issues have now been resolved. In Q3, improvements at the biscuit factory added about NOK 45 million to EBIT growth. Although the biscuit factory improvement was the main driver behind the NOK 53 million underlying EBIT growth in the quarter, growth was still solid, given the big lift in A&P spending versus a year ago. And on cocoa, we want to repeat that volumes for 2024 are secured.
Arve Regland
executiveWe've also begun locking in volumes for Q1 of next year. And although cocoa prices have come down since the spring, they're still exceptionally high relative to historical levels. We keep taking mitigating actions to soften the impact. Finally, a redesigned operating model was presented at Orkla Capital Markets Day last year. The shift to this new model is going well and should be fully in place by early next year. Orkla Food Ingredients posted organic growth of 3.1%. Volume/mix was positive at 4.1%, while prices fell slightly following input price reductions. The Bakery segment carried on its solid performance, driven by volume/mix growth and price management. Volume in the Sweet segment rose during the quarter, partly explained by weak comparables in Q3 last year for ice cream ingredients. We also see that the program of mitigating actions mentioned last quarter is on track per plan. We have a slight year-over-year decline for Plant Based, but that's entirely tied to the margarine segment, where results were temporarily very strong in the second half of 2023, and in particular, in the fourth quarter. The strong underlying EBIT adjusted growth of 18% in the quarter is explained by the organic growth in Bakery and Sweet.
Arve Regland
executiveNow turning to Orkla Health. Organic growth for Orkla Health came in at 10% this quarter, driven by widespread price increases along with sustained solid momentum for Builders and Jotun, plus the Maxine launch in Norway, positive development for Möller's and Jordan through the Maxim relaunch in Norway, and positive development for Riemann and our D2C business. Underlying EBIT adjusted growth of 13% came from top line growth and a favorable mix, though it was partly offset by greater investments in A&P and commercial resources. That aligns with the growth strategy of accelerating international expansion for global brands and new market entries for NutraQ, while also supporting our brands in our Nordic home markets. Organic growth in Orkla India was driven by positive volume/mix development of 3.3% and negative price effects stemming from input price reductions. Strong growth in the international business continues, while consumer sentiment domestically was weak, combined with modest festive sales and distributor inventory reductions. Underlying EBIT adjusted growth was 8.4% in the quarter, driven by contribution margin improvement and lower fixed costs, but partially offset by higher advertising costs. European Pizza Company reported organic growth of 2.3% in the quarter.
Arve Regland
executiveDa Grasso in Poland is still building positive momentum, whereas consumer sales in Finland and the Netherlands stay soft. A strong emphasis on pricing and cost control helped drive underlying EBIT adjusted growth of 23%, though growth also got a positive lift from the turnaround at New York Pizza, Germany, which now runs on a smaller but healthier base. Orkla Home & Personal Care posted organic growth of 4% for the quarter, fueled by higher volumes in contract manufacturing — that means making products for external customers. Underlying EBIT adjusted rose by 25%, helped by revenue management and lower input prices but partly offset by increased advertising spend. Moving to the remaining portfolio companies in the Transform or exit category: all 3 of them faced challenging market conditions during the quarter. I'm impressed that Orkla Health Care nonetheless kept performing in line with the company's financial targets, delivering 17% EBIT growth in the quarter, driven by better cost efficiency plus onboarding of new customers and successful campaigns. So with that, I'd like to hand the floor back to you, Nils.
Nils Selte
executiveThank you, Arve. From where I sit, the Orkla organization has turned in strong results so far this year. Value creation is moving in a positive direction, and I see a growing entrepreneurial spirit among the companies in our portfolio. Adapting continuously is essential, and we aim to remain competitive at every level. That is why, as we reduce and simplify my management team, both Atle Vidar Nagel-Johansen and Christer Gronberg have chosen to take early retirement in 2025. I would like to thank Atle and Christer for their dedicated leadership and their service across the last 25 years. That said, Atle Vidar will stay on as Chair of Orkla India for some time to come. The new Orkla ASA organization takes effect on November 1. Beyond these organizational changes, we are also going through costs at Orkla ASA, with the goal of running a leaner operation that is more cost-efficient. Driving organic value in our current portfolio is my #1 priority. We are only in the third quarter of a 12-quarter strategy period. Our performance is in line with targets. We are seeing high EBIT adjusted growth, margin expansion and a higher return on capital employed. While this partly reflects normalization, these early signs are encouraging. We have begun cutting complexity in our current portfolio, with the sale of Lilleborg in June this year.
Nils Selte
executiveLike we said before, we're also looking at various structural options when it comes to moving Orkla's Hydro Power business. A sales process has been started that covers all or portions of other Hydro Power assets. Once an agreement is reached — if one is — we'll give you an update. I've sensed there may be some confusion in the market — that the Orkla Food Ingredients deal with Rhône, plus what the Capital Market Day assessment for Orkla India involves, are solely about crystalizing value. Let me be clear on that. Both of them show how we're working to locate the right platform for additional growth and value creation. And finally, we'll continue to buy structural opportunities when timing is right. With that, let's go to the Q&A.
Annie Bersagel
executive<<operator_script>> There are a few questions that came in online, so we'll begin there, and the first one is from Eirik Rafdal at Carnegie. Regarding the Hydro Power sales process, he first asked whether you could provide any indication of a timeline. Second, what impact does Saudefaldene have on this? And apart from Saudefaldene, are you able to pursue any potential buyer for the remaining assets, or do any limitations exist from a regulatory standpoint?
Nils Selte
executiveTo start with, on the timeline, I’d rather not give guidance there. I think we’ll run a thorough process and make sure we secure the right price if we reach a sales — a final sale of the assets. As I said, this process also covers all assets across all our Hydro Power assets. And beyond that, we don’t want to offer any further guidance on this matter. Naturally, we reviewed the regulatory issues before launching such a process.
Annie Bersagel
executiveHakon Fuglu from SEB has the second question. First, how confident are you about holding onto the price increases in 2025? And the second one concerns BUBs specifically. What were BUBs' sales over the last 12 months, and what potential is there for taking the brand abroad? So let's begin with the first question. How confident are you that price increases will be maintained in 2025?
Nils Selte
executiveAs we always say, we don’t provide guidance looking ahead. So I will — but what we’ve observed so far in this year is that price increases have been smaller in this year than in the prior years. Apart from that, we don’t want to give guidance looking forward.
Annie Bersagel
executiveAnd regarding BUBs, what were sales over the last 12 months, and how much potential is there for taking the brand into international markets?
Arve Regland
executiveWe don’t break out specifics for each of the categories. What we can say regarding BUBs is that demand is rising. That demand is now worldwide as well. So what we’re doing at BUBs is in fact raising production volumes so we can meet that demand. So we still see a huge perception for that brand around the world.
Annie Bersagel
executiveOle Martin Westgaard from DNB Markets has the next question. Concerning the biscuit factory, he says they understand the operational challenges are now resolved. Did Q3 fully reflect that? Or should a further improvement be expected in Q4?
Nils Selte
executiveDuring last year's Capital Markets Day, we stated that a substantial portion of the NOK 150 million expense incurred in the prior year would recur in the current one. That remains true, and our guidance on it is unchanged. As a result, we will observe a modest impact in the Q4 figures as well.
Annie Bersagel
executiveOle Martin's second question is about how we should view the effect on cocoa prices for next year at Orkla Confectionery & Snacks. Will price increases let you offset that?
Nils Selte
executiveLike I mentioned, we aren't giving specific guidance tied to the market on that. For this year, and partly into the first quarter of next year as well, we've got our volumes covered, and that's all we want to say regarding how cocoa prices affect this year. Should cocoa stay at this level, we'll keep raising prices if we need to.
Annie Bersagel
executiveMoving on to the next question. Petter Nyström from ABG has two questions. First, you mentioned reviewing costs at Orkla ASA — could you possibly share a bit more detail on that?
Nils Selte
executiveWe’ll come back to that afterward. We’re in the process of examining every cost within our class, and we’ve already taken a look at the market, perhaps in Q4 of this year.
Annie Bersagel
executivePetter also sent us a question about India. In his question, he notes that sales growth in India came in relatively soft during Q3. Could you provide a bit more detail on how things developed in India?
Nils Selte
executiveLooking at India, peer sales show some softness during Q3. The market there is dealing with its own conditions, and naturally consumer spending and confidence are being pressured since inflation has been running pretty high on certain food prices, so to speak. That carries through into our value chain as well. Our performance in India for the third quarter, I'd say, matches what our peers delivered. In our view, this represents a short-term dip in the market.
Annie Bersagel
executiveThat was the last question submitted online. Does anyone else in the audience have a question? Nothing? Before we wrap up, I want to remind everyone that our fourth quarter results will be reported on February 13. Thanks once more for being with us, and have a good rest of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Orkla ASA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Orkla ASA earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Orkla ASA or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.